While overall risk of macular degeneration remained low, a study suggests that GLP-1 drugs may have increased that risk in ...

For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Patients with diabetes who utilize GLP-1 RAs for 6 months or longer are twice as likely to develop neovascular age-related macular degeneration.

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Healthcare companies are navigating a challenging environment as policy uncertainty and competitive pressures weigh on the ...

This became a source of contempt from the neighboring kids whose fathers tilled the land. My dad walked into his office in ...

Although osteoarthritis is receiving more attention in both the research and clinical arenas than ever, all that attention ...

We've all heard eating less sugar helps melt off spare pounds. Yet it often feels too darn hard. So we were excited when we ...

Even though diet culture often frames snacking as a negative—an unbridled act of gluttony at best, and a sign of moral ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies in a ...